In autoimmune disorders, the body’s defense system erroneously attacks normal cells, leading to serious health problems. Researchers have developed new molecules that potentially could be used to treat many of these conditions.
Rockefeller scientists have identified a genetic condition that makes people prone to developing tuberculosis. In a British population, they found that the condition underlies one percent of cases of the disease—a finding that may ultimately lead to new treatment options.
Recent research has shown that a drug known as MI-2 can kill cells that cause a fatal brain cancer. But only now have scientists been able to explain how the compound works: by targeting cholesterol production in tumors.
Some cancers have been traced to changes in histones, proteins responsible for packaging DNA and regulating genes. Now, research from Rockefeller scientists shows that, among tumors, mutations to these proteins are a lot more common than previously suspected.
Scientists discovered a protein that plays a crucial role in regulating fatty acids, the molecules that make up body fat. This research could lead to new options for treating people with diseases associated with fatty acid buildup.
New research on leptin, a hormone that regulates appetite, reveals a previously unknown mechanism that may be responsible for at least 10 percent of obesity cases. The findings could help identify individuals with treatable forms of the condition.
Researchers have identified a rare type of cancer cell that cannot make cholesterol, a key nutrient. By targeting this deficiency, scientists may be able to develop new strategies for treating the disease.
Increasingly, bacteria do not succumb to antibiotics. Rockefeller researchers have developed a new class of antimicrobial drug, lysin, with one compound showing promising results in a clinical trial—suggesting that an alternative to antibiotics may be on the horizon.